CliffBio
biologic

Padcev

enfortumab vedotin-ejfv

Loss of exclusivityDecember 2031projected — 12-year biologic exclusivity estimate
CompanyAstellas Pharma Us →View the full company profile on CliffBio

Drug detail

Brand namePadcev
Active ingredientenfortumab vedotin-ejfv
Strength30MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2019
Marketing statusRx

More from Astellas Pharma Us

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Padcev patent cliff — loss of exclusivity December 2031 | CliffBio